What do systematic reviews say?

Methotrexate vs other DMARDs

• Methotrexate for psoriatic arthritis 2019 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 61 participants
  Very low

Methotrexate vs other DMARDs

• Methotrexate for psoriatic arthritis 2019 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 61 participants
  Very low
• Methotrexate for psoriatic arthritis 2019 · Cochrane Headline outcomes only
  RR 1.26 [0.33, 4.82]
  1 study · 35 participants
  Very low

Methotrexate vs other DMARDs

• Methotrexate for psoriatic arthritis 2019 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 35 participants
  Very low

Methotrexate vs placebo

• Methotrexate for psoriatic arthritis 2019 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 221 participants
  Low

Methotrexate vs placebo

The review found no eligible studies for this question.

• Methotrexate for psoriatic arthritis 2019 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Methotrexate vs placebo

• Methotrexate for psoriatic arthritis 2019 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 221 participants
  Low

Methotrexate vs placebo

The review found no eligible studies for this question.

• Methotrexate for psoriatic arthritis 2019 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Methotrexate vs placebo

Methotrexate showed no clear difference in serious adverse events (SAEs) assessed by number of events compared with placebo (low certainty).

• Methotrexate for psoriatic arthritis 2019 · Cochrane Headline outcomes only
  RR 0.26 [0.03, 2.26]
  3 studies · 293 participants
  Low

Methotrexate vs placebo

Methotrexate showed no clear difference in withdrawals due to adverse events (WAEs) assessed by number of events compared with placebo (low certainty).

• Methotrexate for psoriatic arthritis 2019 · Cochrane Headline outcomes only
  RR 1.32 [0.51, 3.42]
  3 studies · 293 participants
  Low

Methotrexate vs other DMARDs

It is very uncertain whether methotrexate changes disease response (leflunomide) compared with other DMARDs (very low certainty).

• Methotrexate for psoriatic arthritis 2019 · Cochrane Headline outcomes only
  RR 1.05 [0.77, 1.45]
  1 study · 30 participants
  Very low

Methotrexate vs other DMARDs

• Methotrexate for psoriatic arthritis 2019 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 31 participants
  Very low

Rituximab (2 x 1000 mg) plus methotrexate vs methotrexate

Rituximab (2 x 1000 mg) plus methotrexate probably leads to higher clinical improvement American College of Rheumatology 50%… compared with methotrexate monotherapy (moderate certainty).

• Rituximab for rheumatoid arthritis 2015 · Cochrane Headline outcomes only
  RR 3.3 [2.3, 4.6]
  4 studies · 1165 participants
  Moderate

Rituximab (2 x 1000 mg) plus methotrexate vs methotrexate

Rituximab (2 x 1000 mg) plus methotrexate showed no clear difference in clinical remission (Disease Activity Score‐28 joint count < 2.6)… compared with methotrexate monotherapy (moderate certainty).

• Rituximab for rheumatoid arthritis 2015 · Cochrane Headline outcomes only
  RR 9.1 [0.76, 108.2]
  2 studies · 834 participants
  Moderate

Rituximab (2 x 1000 mg) plus methotrexate vs methotrexate

Rituximab (2 x 1000 mg) plus methotrexate leads to higher physical function (HAQ‐DI MCID = ‐0.22) Analysis 1.10 compared with methotrexate monotherapy (high certainty).

• Rituximab for rheumatoid arthritis 2015 · Cochrane Headline outcomes only
  RR 1.6 [1.2, 2.1]
  4 studies · 1161 participants
  High

Rituximab (2 x 1000 mg) plus methotrexate vs methotrexate

Rituximab (2 x 1000 mg) plus methotrexate showed no clear difference in no radiographic progression in total Genant‐modified Sharp score… compared with methotrexate monotherapy (moderate certainty).

• Rituximab for rheumatoid arthritis 2015 · Cochrane Headline outcomes only
  RR 1.2 [1, 1.4]
  1 study · 476 participants
  Moderate

Rituximab (2 x 1000 mg) plus methotrexate vs methotrexate

Rituximab (2 x 1000 mg) plus methotrexate leads to higher health‐related quality of life compared with methotrexate monotherapy (high certainty).

• Rituximab for rheumatoid arthritis 2015 · Cochrane Headline outcomes only
  RR 2 [1.1, 3.4]
  4 studies · 1526 participants
  High

Rituximab (2 x 1000 mg) plus methotrexate vs methotrexate

Rituximab (2 x 1000 mg) plus methotrexate showed no clear difference in discontinuations due to adverse events Analysis 6.3 compared with methotrexate monotherapy (moderate certainty).

• Rituximab for rheumatoid arthritis 2015 · Cochrane Headline outcomes only
  RR 2.1 [0.88, 4.9]
  5 studies · 1385 participants
  Moderate

Rituximab (2 x 1000 mg) plus methotrexate vs methotrexate

Rituximab (2 x 1000 mg) plus methotrexate showed no clear difference in serious adverse events Analysis 11.2 compared with methotrexate monotherapy (moderate certainty).

• Rituximab for rheumatoid arthritis 2015 · Cochrane Headline outcomes only
  RR 1 [0.69, 1.5]
  4 studies · 1280 participants
  Moderate

Summary of findings: leflunomide + methotrexate vs methotrexate

• Leflunomide for the treatment of rheumatoid arthritis 2002 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 263 participants
  High

Summary of findings: leflunomide + methotrexate vs methotrexate

• Leflunomide for the treatment of rheumatoid arthritis 2002 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 263 participants
  Moderate